Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

Voci, Davide; Götschi, Andrea; Held, Ulrike; Bingisser, Roland; Colucci, Giuseppe; Duerschmied, Daniel; Fumagalli, Riccardo M.; Gerber, Bernhard; Hasse, Barbara; Keller, Dagmar I.; Konstantinides, Stavros; Mach, François; Rampini, S; Righini, Marc; Robert‐Ebadi, Helia; Rosemann, Thomas; Roth-Zetzsche, Stéphanie; Sebastian, Tim; Simon, Noemi R; Spirk, David; Stortecky, Stefan; Vaisnora, Lukas; Kucher, Nils

doi:10.1016/j.thromres.2022.10.021

Cited by 13 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thromboprophylaxis with enoxaparin did not reduce early hospitalizations and deaths among outpatients with symptomatic COVID-19 [24] . In adult community patients with COVID-19, early thromboprophylaxis with enoxaparin did not improve the course of COVID-19 neither in terms of hospitalization and death nor considering COVID-19-related symptoms [25] . The ETHIC trial also suggested that prophylaxis with LMWH had no benefit for at-risk outpatients with COVID-19 [26] .…”

Section: Discussionmentioning

confidence: 81%

The impacts of prophylactic anticoagulation therapy during hospitalization on long-term cardiovascular outcomes in high-risk COVID-19 patients amid the omicron wave of the pandemic

Gu,

Wang,

Zhang

et al. 2024

IJC Heart & Vasculature

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 81%

The impacts of prophylactic anticoagulation therapy during hospitalization on long-term cardiovascular outcomes in high-risk COVID-19 patients amid the omicron wave of the pandemic

Gu,

Wang,

Zhang

et al. 2024

IJC Heart & Vasculature

View full text Add to dashboard Cite

“…Moreover, three studies investigated the use of additional antiplatelet therapy, primarily P2Y12 agonists, with one study also including aspirin in the treatment. Furthermore, three studies 19 , 39 , 41 explored postdischarge prophylaxis and four studies 15 , 16 , 18 , 40 explored prophylactic anticoagulation for outpatients, with one study 18 using LMWH (Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…Four studies 15 , 16 , 18 , 40 compared the use of prophylactic anticoagulation or no anticoagulation for outpatient. The results showed no statistically significant difference in thromboembolism events (RR, 0.50; 95% CI: 0.19–1.20) (Fig.…”

Section: Resultsmentioning

confidence: 99%

Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient, and postdischarge prophylaxis: a meta-analysis of randomized controlled trials

Meng,

Tang,

Xiao

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

Background: There was controversy surrounding the optimal thromboprophylaxis strategy for COVID-19 patients. This included debates on the dosage of anticoagulants for thromboembolism prophylaxis, the requirement for additional antiplatelet therapy, and the necessity of prophylaxis for outpatients and post-discharge. To explore this, we performed a meta-analysis of randomized controlled trials. Methods: PubMed, Cochrane Library, Embase, and Web of Science were last searched on 26 July 2023 for studies comparing the effect of different dose of anticoagulation, additional antiplatelet and post-discharge prophylaxis for COVID-19 patients. The results of eligible studies were analyzed in terms of thromboembolism events, major bleeding and all-cause mortality during follow-up. Results: Our study included a total of 25 randomized controlled trials, involving 17,911 patients. Our results revealed that, compared to prophylactic dose, therapeutic dose showed lower thrombotic risk (RR, 0.66; 95%CI, 0.45 to 0.96) but had similar major bleeding risk for critically ill patients with COVID-19. On the other hand, intermediate dose and prophylactic dose demonstrated similar thromboembolism risk and major bleeding risk. For non-critically ill patients with COVID-19, therapeutic dose of anticoagulants was associated with lower thrombotic risk (RR, 0.50; 95%CI 0.34 to 0.72) but, at the same time, increased the risk of major bleeding (RR, 2.01; 95%CI 1.22 to 3.33). However, intermediate dose showed lower thromboembolism risk (RR, 0.38; 95%CI 0.21 to 0.69) while maintaining a similar major bleeding risk. In critically ill patients, additional antiplatelet therapy showed similar thromboembolism, major bleeding risk, and mortality when compared to no treatment. For outpatients, additional prophylactic anticoagulation showed similar thromboembolism, major bleeding risk, and mortality when compared to no treatment. For post-discharge patients, post-discharge prophylaxis reduced thromboembolism risk (RR, 0.49; 95%CI 0.31 to 0.76) but increased major bleeding risk (RR, 2.63; 95%CI, 1.13 to 6.14). Conclusion: For non-critically ill patients, therapeutic dose prophylactic anticoagulation significantly reduced venous thromboembolism but increases major bleeding risk. Intermediate dose effectively lowered venous thromboembolism without raising major bleeding risk. The optimal dose and need for additional antiplatelet therapy in critically ill patients, as well as the necessity of prophylactic anticoagulation in outpatient and post-discharge patients, required further investigation and confirmation through rigorous evidence studies.

show abstract

COVID-19 und VTE-Prophylaxe

Langer

2023

Klinische Angiologie

View full text Add to dashboard Cite

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

Cited by 13 publications

References 26 publications

The impacts of prophylactic anticoagulation therapy during hospitalization on long-term cardiovascular outcomes in high-risk COVID-19 patients amid the omicron wave of the pandemic

The impacts of prophylactic anticoagulation therapy during hospitalization on long-term cardiovascular outcomes in high-risk COVID-19 patients amid the omicron wave of the pandemic

Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient, and postdischarge prophylaxis: a meta-analysis of randomized controlled trials

COVID-19 und VTE-Prophylaxe

Contact Info

Product

Resources

About